HER2-antigen specific cancer immunotherapeutic

Drug Profile

HER2-antigen specific cancer immunotherapeutic

Alternative Names: dHER2+AS15; dHER2+AS15 ASCI; HER2 ASCI; Recombinant HER2 protein - GlaxoSmithKline

Latest Information Update: 23 Jul 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines; Recombinant proteins
  • Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Dec 2006 Phase-II clinical trials in Breast cancer in Australia (IV-injection)
  • 04 Dec 2006 Phase-II clinical trials in Breast cancer in Belgium (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top